PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Dynavax Technologies Corporation (DVAX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US2681582019

CUSIP

268158201

Sector

Healthcare

IPO Date

Feb 19, 2004

Highlights

Market Cap

$1.72B

EPS (TTM)

$0.15

PE Ratio

87.27

Total Revenue (TTM)

$205.22M

Gross Profit (TTM)

$169.18M

EBITDA (TTM)

$34.01M

Year Range

$9.74 - $13.89

Target Price

$24.40

Short %

18.05%

Short Ratio

10.64

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
DVAX vs. SCHD DVAX vs. VOO DVAX vs. NIO
Popular comparisons:
DVAX vs. SCHD DVAX vs. VOO DVAX vs. NIO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Dynavax Technologies Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%-5.00%0.00%5.00%10.00%15.00%20.00%25.00%SeptemberOctoberNovemberDecember2025February
18.17%
9.82%
DVAX (Dynavax Technologies Corporation)
Benchmark (^GSPC)

Returns By Period

Dynavax Technologies Corporation had a return of 4.39% year-to-date (YTD) and 6.98% in the last 12 months. Over the past 10 years, Dynavax Technologies Corporation had an annualized return of -2.73%, while the S&P 500 had an annualized return of 11.26%, indicating that Dynavax Technologies Corporation did not perform as well as the benchmark.


DVAX

YTD

4.39%

1M

5.13%

6M

18.17%

1Y

6.98%

5Y*

22.34%

10Y*

-2.73%

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of DVAX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20252.19%4.39%
2024-7.58%-1.93%-2.05%-8.38%5.45%-6.34%-0.36%0.27%-0.71%6.37%8.52%-0.70%-8.66%
20236.95%-9.49%-4.76%6.12%9.80%13.04%8.28%2.64%2.86%-3.79%-3.59%2.04%31.39%
2022-7.82%-5.47%-11.58%-18.54%34.31%6.16%14.22%-20.24%-8.98%9.67%8.38%-14.26%-24.38%
202141.80%38.67%12.34%1.53%-17.84%20.12%-5.18%108.35%-1.28%3.96%-19.13%-12.88%216.18%
2020-11.71%-21.88%-10.52%20.40%44.00%44.93%-8.57%-26.26%-27.76%-13.66%36.19%-12.40%-22.20%
201920.44%-16.52%-20.54%-9.03%-27.52%-17.22%-30.83%50.00%-13.65%42.38%11.00%1.24%-37.49%
2018-13.90%0.31%22.91%-14.61%-6.78%-3.48%-11.48%2.59%-10.47%-20.24%14.26%-19.03%-51.07%
20173.80%9.76%32.22%-6.72%-0.90%75.45%64.25%13.25%19.78%2.33%-9.09%-6.50%373.42%
2016-0.29%-33.08%19.35%-14.71%1.10%-12.12%5.83%1.49%-33.01%-11.82%-53.51%-8.14%-83.65%
20151.42%2.92%27.44%-10.32%13.20%2.88%25.55%-3.57%-13.47%-7.46%22.81%-13.37%43.30%
2014-11.22%6.90%-2.82%-9.82%-11.66%11.11%-7.50%-4.05%0.70%14.69%-9.39%13.46%-13.98%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of DVAX is 50, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of DVAX is 5050
Overall Rank
The Sharpe Ratio Rank of DVAX is 5555
Sharpe Ratio Rank
The Sortino Ratio Rank of DVAX is 4747
Sortino Ratio Rank
The Omega Ratio Rank of DVAX is 4545
Omega Ratio Rank
The Calmar Ratio Rank of DVAX is 5050
Calmar Ratio Rank
The Martin Ratio Rank of DVAX is 5454
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Dynavax Technologies Corporation (DVAX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for DVAX, currently valued at 0.23, compared to the broader market-2.000.002.000.231.74
The chart of Sortino ratio for DVAX, currently valued at 0.57, compared to the broader market-4.00-2.000.002.004.006.000.582.36
The chart of Omega ratio for DVAX, currently valued at 1.07, compared to the broader market0.501.001.502.001.071.32
The chart of Calmar ratio for DVAX, currently valued at 0.08, compared to the broader market0.002.004.006.000.082.62
The chart of Martin ratio for DVAX, currently valued at 0.62, compared to the broader market-10.000.0010.0020.0030.000.6210.69
DVAX
^GSPC

The current Dynavax Technologies Corporation Sharpe ratio is 0.23. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Dynavax Technologies Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
0.23
1.74
DVAX (Dynavax Technologies Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Dynavax Technologies Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-86.47%
-0.43%
DVAX (Dynavax Technologies Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Dynavax Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Dynavax Technologies Corporation was 98.47%, occurring on Nov 20, 2008. The portfolio has not yet recovered.

The current Dynavax Technologies Corporation drawdown is 86.47%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.47%Dec 12, 2006490Nov 20, 2008
-61.81%Feb 20, 2004291Apr 15, 2005410Nov 29, 2006701
-7.25%Nov 30, 20062Dec 1, 20066Dec 11, 20068

Volatility

Volatility Chart

The current Dynavax Technologies Corporation volatility is 7.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
7.63%
3.01%
DVAX (Dynavax Technologies Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Dynavax Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of Dynavax Technologies Corporation compared to its peers in the Drug Manufacturers - Specialty & Generic industry.


PE Ratio
20.040.060.080.087.3
The chart displays the price to earnings (P/E) ratio for DVAX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a PE value of 87.3. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-150.0-100.0-50.00.00.0
The chart displays the price to earnings to growth (PEG) ratio for DVAX in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, DVAX has a PEG value of 0.0. This PEG ratio falls in the average range for the industry.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Dynavax Technologies Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab